Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

On discounting of health gains from human papillomavirus vaccination: effects of different approaches.

Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C, Postma MJ.

Value Health. 2012 May;15(3):562-7. doi: 10.1016/j.jval.2012.01.005. Epub 2012 Mar 29.

2.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
3.

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark.

Olsen J, Jepsen MR.

Int J Technol Assess Health Care. 2010 Apr;26(2):183-91. doi: 10.1017/S0266462310000085.

PMID:
20392322
4.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
5.

Counting and discounting gained life-years.

Søgaard J, Gyrd-Hansen D.

Dev Health Econ Public Policy. 1998;6:51-74.

PMID:
10662409
6.

Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.

Obradovic M, Mrhar A, Kos M.

Eur J Public Health. 2010 Aug;20(4):415-21. doi: 10.1093/eurpub/ckp208. Epub 2010 Jul 12.

7.

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.

8.

Health and economic impact associated with a quadrivalent HPV vaccine in Italy.

Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N.

Gynecol Oncol. 2009 Feb;112(2):370-6. doi: 10.1016/j.ygyno.2008.09.031. Epub 2008 Nov 28.

PMID:
19041125
9.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

10.

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9. doi: 10.1017/S0266462307080026.

PMID:
18218164
11.

Discounting health effects in pharmacoeconomic evaluations: current controversies.

Bos JM, Postma MJ, Annemans L.

Pharmacoeconomics. 2005;23(7):639-49.

PMID:
16173156
12.

Discounting in the economic evaluation of health care interventions.

Krahn M, Gafni A.

Med Care. 1993 May;31(5):403-18. Review.

PMID:
8501989
13.

Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.

Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N.

Int J Gynecol Cancer. 2010 Apr;20(3):385-92. doi: 10.1111/IGC.0b013e3181d189b8.

PMID:
20375802
14.

Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.

Jit M, Mibei W.

Vaccine. 2015 Jul 31;33(32):3788-94. doi: 10.1016/j.vaccine.2015.06.084. Epub 2015 Jul 2. Review.

15.

HPV vaccination in France: uptake, costs and issues for the National Health Insurance.

Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H.

Vaccine. 2011 Apr 27;29(19):3610-6. doi: 10.1016/j.vaccine.2011.02.064. Epub 2011 Mar 5.

PMID:
21382486
16.

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.

Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):459-66.

17.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

18.

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.

Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-000000000-00000.

PMID:
21838332
19.

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting.

Kim JJ, Andres-Beck B, Goldie SJ.

Br J Cancer. 2007 Nov 5;97(9):1322-8. Epub 2007 Oct 9.

20.

The cost-effectiveness of male HPV vaccination in the United States.

Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.

Vaccine. 2011 Oct 26;29(46):8443-50. doi: 10.1016/j.vaccine.2011.07.096. Epub 2011 Aug 2.

PMID:
21816193
Items per page

Supplemental Content

Write to the Help Desk